



## The SOLNATIDE project

### Exploration of safety, tolerability and clinical efficacy of Solnatide IMP in patients infected with the 2019 new Coronavirus

#### The Challenge

Patients infected with the **new Coronavirus** (2019-nCoV, Covid-19) suffer from severe respiratory failure, and presence of a life-threatening pulmonary oedema (PPO). Approximately 30% of Covid-2019 patients further develop life-threatening **Acute Respiratory Distress Syndrome (ARDS)** resulting in a very high mortality rate. To date, no medicine has been approved for the therapeutic treatment of Pulmonary Permeability Oedema and ARDS.

#### The Solution

The SOLNATIDE project will clinically test peptide-based products targeting **life-threatening pulmonary diseases** (e.g. oedematous respiratory failure, acute lung injury). APEPTICO's **lead-compound Solnatide (IMP)** has been designed for the therapeutic treatment of patients with **Acute Respiratory Distress Syndrome (ARDS)** and various forms of Pulmonary Oedema (PPO).

Orally inhaled Solnatide has **delivered clinical proof-of-concept in one Phase I and two Phase II clinical studies** (EUDRACT No. 2011-000223-33, 2012-001863-64, 2013-000716-21). Currently, Solnatide is subject to a **Phase IIB trial** (EUDRACT No. 2017-003855-47) with clinical trials approved by competent authorities and ethics committees in Germany and Austria. The SOLNATIDE project will generate clinical trial results **assessing safety, tolerability and clinical efficacy of Solnatide IMP in Covid-19 patients**.

#### The SOLNATIDE project in a nutshell

**Funding:** €1.626 million

**Funding:** European Commission (EC) call "H2020-SC1-PHE-CORONAVIRUS-2020" (grant no. 101003595)

**Project start:** April 1<sup>st</sup> 2020

**Duration:** 21 months

**Consortium:** 5 partners from Austria, Germany, Italy and Spain:

RTDS Association ([www.rtds-group.com](http://www.rtds-group.com)), AT – Coordinator, Project & Communication Management

APEPTICO Forschung und Entwicklungs GmbH (<http://apeptico.com/>), AT – Scientific coordinator

BCN Peptides SA (<http://www.bcnpeptides.com/>), ES

Ludwig-Maximilians-University Munich (LMU) University Hospital (<https://www.lmu-klinikum.de/>), GER

OPIS SRL (<https://opis-europe.com/en>), IT

**Contact:** RTDS, [solnatide@rtds-group.com](mailto:solnatide@rtds-group.com), +43-(0)1-3231000-11, Lerchengasse 25/2-3, A-1080 Vienna, Austria.

**Website:** <http://www.rtds-group.com/projects/solnatide/>

This project has received funding from the EU special H2020 program "Advancing knowledge for the clinical and public health response to the 2019-nCoV epidemic (call ID: SC1-PHE-CORONAVIRUS-2020)" under the grant no. 101003595.

